Tagworks Pharmaceuticals is a privately held therapeutics company based in the Netherlands. It leverages unique technologies to increase efficacy and decrease toxicity across multiple systemic treatment modalities.

The company has pioneered a unique and proprietary Click-to-Release drug development technology, enabling the selective release of anticancer drugs in the tumor microenvironment. This platform has a broad set of application areas (antidrug conjugates, radioligands, T cell engagers, and cytokines), and has the potential to increase antitumor efficacy while lowering potential toxicity for patients. With a focus on addressing the high unmet need and mortality rates in ovarian cancer, Tagworks’ innovative approach holds promise for more effective treatment across various solid tumors.

Tagworks raised a €60m Series A financing co-led by Gilde Healthcare to further develop its differentiated click chemistry platform and bring drug candidates to the clinic.